Abstract Details

Title Understanding HD Psychosis: An Analysis from the ENROLL-HD Database

Topic Movement Disorders

Presentation(s) S16 - Huntington's Disease: From Bench to Clinical Trials (1:33 PM-1:44 PM)

Poster/Presentation
Number 004

Background Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by progressive neuropsychiatric deterioration. Psychosis is thought to be rare in HD (prevalence of 3-11% in various studies), but likely has a significant negative impact on quality of life and disease burden.

Objective To use a large database to determine the prevalence, onset, and severity of psychosis in HD, and to determine what demographic and disease characteristics are associated with psychosis.

Design/Methods Data were obtained from Enroll-HD. Adults with manifest HD were included. Presence of psychosis was determined by investigator response to, “Has psychosis (hallucinations or delusions) ever been a part of the participant’s medical history?” Descriptive statistics were calculated. Bivariate comparisons were conducted for demographic and disease characteristics between those with and without psychosis. Logistic regression was used to identify significant factors associated with psychosis. ORs with 95% CIs were calculated.

Results 4,727 manifest HD subjects were analyzed, and 11.72% had a history of psychosis. Mean age of onset of psychosis (47.6 years, SD 13.68) mirrored onset of HD. Family history of psychosis in a first degree relative was documented in 27.5% of subjects with psychosis. Variables significantly (p<0.05) associated with higher rates of psychosis in our multivariate model were: non-white race (OR 2.07), being single (OR 2.45) or formerly married (OR 1.87), lack of formal education beyond high school (OR 1.67), history of violent behavior (OR 2.03), history of apathy (OR 1.84), history of obsessive behaviors (OR 2.11). The odds of psychosis increase by a factor of 1.10 for every 1 unit decrease in the functional assessment score.

Conclusions Psychosis in HD is more common than many prior studies have reported. It is associated with worse functional outcomes. Our findings suggest several predictors that could be useful in improving our understanding of psychosis in this population.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Danny Bega, MD (Northwestern University)	Dr. Bega has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GE Healthcare. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WebMD. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acorda Therapeutics. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine Biosciences. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ACTN / ANA. The institution of Dr. Bega has received research support from Huntington Disease Society of America. The institution of Dr. Bega has received research support from Parkinson Foundation.

��ɫ��

��ɫ��